Biohaven .(US:BHVN) Financial Modeling Prep·2026-03-02 17:00Core Insights - Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on therapies for neurological and immunoscience diseases, attracting investor and analyst attention due to its innovative treatment approaches [1] - The average price target for Biohaven increased to $23 last month, reflecting a positive outlook from analysts compared to the previous quarter, with BTIG setting a target of $24, indicating a potential rally of 82.2% [2][6] - Analysts' optimism is supported by an increase in the average price target from $18.67 three months ago to $23, suggesting favorable developments in clinical trials or market conditions [3] - A year ago, the average price target was $31.5, indicating challenges over the past year, but the recent upward trend suggests potential recovery and positive developments, with Biohaven receiving a Zacks Rank 2 (Buy) [4] - Recent news, including clinical trial progress and regulatory approvals, could significantly impact analysts' expectations and price targets, with positive developments likely leading to further increases [5]